TOVX TOVX
Company Profile ↓Company Overview
TOVX (TOVX) is a publicly traded company listed on with a market capitalization of $8.21M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.17.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -47.65% |
| 6 Months: | +25.06% |
| 3 Months: | -40.76% |
| 1 Month: | -6.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 73.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 300.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.42M | 13.13M | 4.44M | 2.06M | 2.43M |
| Operating Income | -8.21M | -9.73M | -11.65M | - | -10.58M | -9.31M | -9.16M | - | -8.15M | -6.47M | -5.84M | - | -4.99M | -5.00M | -4.32M | - | -3.57M | -3.64M | -5.24M | -3.03M | -2.89M | -2.11M | -2.54M | -3.20M | -3.27M | -4.25M | -5.03M | -4.99M | -5.18M | -5.82M | -4.22M | -5.39M | -8.49M | -7.89M | - | -4.42M | -13.13M | -4.44M | -2.06M | -2.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.39M | -13.11M | -4.41M | -2.04M | -2.10M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.32M | -13.06M | -4.36M | -2.00M | -2.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -12.36M | -13.62M | -7.51M | -11.30M | -11.08M | -5.76M | -8.49M | -2.47M | -3.06M | -4.32M | -10.93M | 2.81M | -2.32M | -4.20M | -3.68M | -3.19M | -3.51M | -3.53M | -5.12M | -2.96M | -2.87M | -2.10M | -2.54M | -3.19M | -3.27M | -4.27M | -4.48M | -4.49M | - | - | -3.30M | - | - | - | - | -4.32M | -13.06M | -4.36M | -2.00M | -2.04M |
| Diluted EPS | -0.17 | -0.19 | -0.12 | -0.12 | -0.12 | -0.10 | -0.09 | -0.02 | -0.70 | -1.05 | -4.90 | 0.76 | -0.65 | -1.16 | -0.93 | -1.12 | -0.25 | -0.23 | -0.31 | - | - | -0.14 | -0.13 | -0.24 | -0.25 | -0.31 | -0.28 | -0.30 | -0.30 | -0.34 | -4.85 | -7.53 | -10.72 | -6.81 | - | -1.55 | -1.93 | -0.45 | - | -0.05 |
| R&D Expense | 6.49M | 7.51M | 10.05M | - | 8.15M | 7.16M | 7.06M | - | 6.06M | 4.83M | 4.14M | - | 3.37M | 3.57M | 2.85M | - | 2.42M | 2.59M | 4.14M | 1.64M | 1.60M | 914.00K | 1.12M | 1.93M | 1.97M | 2.60M | 3.48M | 2.57M | 2.98M | 3.13M | 4.01M | 3.46M | 2.95M | 2.73M | - | 2.97M | 1.95M | 2.55M | - | 355.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.61M | 0 | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 21.58M | 21.43M | 19.43M | 24.05M |
| Operating Income | - | - | -17.30M | -12.34M | -20.50M | -40.98M | -39.25M | -26.25M | -17.57M | -15.66M | -10.16M | - | -21.58M | -21.43M | -19.43M | -24.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -21.50M | -21.30M | -19.29M | -23.94M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -21.11M | -19.99M | -25.65M | -23.74M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -1.43M | -1.64M | 0 | 0 |
| Net Income | -1.71M | -8.15M | -17.07M | -12.32M | -19.78M | -43.74M | -27.25M | -15.17M | -13.37M | -15.30M | -10.04M | - | -19.68M | -18.35M | -25.65M | -23.74M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.66 | - | -32.75 | -28.48 | -19.03 | -2.08 |
| R&D Expense | 1.58M | 3.34M | 12.29M | 6.51M | 14.49M | 32.91M | 29.11M | 18.78M | 11.84M | 11.08M | 5.13M | 7.80M | 11.72M | 14.31M | 12.03M | 8.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Feb 2019 | Sep 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 4.11M | 7.48M | 13.42M | 16.26M | 19.14M | 30.84M | 22.50M | 18.84M | 30.14M | - | - | 17.23M | 8.41M | - | - | 80.64M | 77.11M | 71.86M | 55.22M | 35.35M | 38.24M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.52M | 27.40M | 16.28M | 17.47M |
| Cash & Equivalents | - | - | 6.68M | 9.95M | 14.62M | 17.52M | 20.82M | 19.05M | 17.12M | 28.92M | 26.00M | - | 15.04M | 6.23M | - | - | 52.27M | 50.49M | 41.79M | 23.18M | 11.61M | 13.06M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 231.00K | 1.94M | 3.32M | 3.83M |
| Total Liabilities | - | 532.00K | 417.00K | 395.00K | 1.03M | 9.59M | 15.84M | 20.25M | 10.20M | 3.69M | - | - | 5.75M | 3.15M | - | - | 18.42M | 17.99M | 17.30M | 15.52M | 16.29M | 22.86M |
| Current Liabilities | - | 500.00K | 417.00K | 395.00K | 1.03M | 9.59M | 15.57M | 19.76M | 9.79M | 3.38M | - | - | 5.28M | 2.97M | - | - | 12.42M | 12.32M | 7.06M | 6.74M | 7.58M | 10.01M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 221.00K | 162.00K | 92.00K | 1.67M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.68M | 2.15M | 1.56M | 2.63M |
| Total Equity | 3.54M | 3.58M | 7.06M | 13.03M | 15.23M | 9.56M | 16.05M | 3.85M | -1.50M | 17.07M | - | 4.93M | 1.82M | -4.77M | - | 68.03M | 62.22M | 56.39M | 54.56M | 39.70M | 19.07M | 15.38M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 633.76K | 714.73K | 2.81M | 35.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.15M | -2.88M | -8.92M | -7.72M | -16.08M | -38.89M | -27.90M | -20.20M | -17.28M | -13.87M | -12.17M | - | -19.08M | -19.00M | -16.94M | -16.67M |
| Investing Cash Flow | - | 65.00K | -75.00K | -10.00K | -36.00K | -48.00K | -501.00K | -569.00K | -212.00K | -7.00K | 0 | -9.00K | - | -4.40M | -202.00K | -1.00K | -35.00K |
| Financing Cash Flow | - | 1.01M | 6.98M | 12.20M | 12.43M | 19.03M | 42.68M | 26.71M | 18.48M | 29.09M | 0 | 3.36M | - | -1.93M | 625.00K | 5.50M | 18.19M |
| Capital Expenditure | - | -12.00K | -0 | -10.00K | -36.00K | -48.00K | -501.00K | -569.00K | -212.00K | -7.00K | -0 | -9.00K | - | -116.00K | -202.00K | -1.00K | -35.00K |
| Free Cash Flow | - | -1.16M | -2.88M | -8.93M | -7.75M | -16.13M | -39.39M | -28.47M | -20.42M | -17.29M | -13.87M | -12.18M | - | -19.20M | -19.20M | -16.94M | -16.70M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.41M | -18.57M | -11.44M | 1.49M |
| Share Buybacks | 1.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | -65.5% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -47.8% | -115.4% | -131.0% | -80.9% | -207.0% | -272.5% | -708.8% | 1,014.3% | -78.3% | -840.4% | 210.7% | - | -36.1% | -46.2% | -134.5% | -154.3% |
| ROCE % | - | - | -132.8% | -81.0% | -214.5% | -268.4% | -1,432.0% | -290.2% | -65.7% | -131.0% | -186.6% | - | -33.3% | -44.2% | -70.0% | -85.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TOVX
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from the recent VIRAGE study and feedback from the EMA and …
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab – – Pharmacokinetic, tissue bio…
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) – – Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic P…
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including pati…
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously fr…
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalti…
TOVX — Frequently Asked Questions
What is the current share price of TOVX?
As of 2026-08-05 17:25 PDT, TOVX trades at $0.23 on NASDAQ/NYSE. Its 52-week range is $0.18 to $0.84.
What is the market capitalisation of TOVX?
TOVX has a market capitalisation of $8.21M on NASDAQ/NYSE.
What is the P/E ratio of TOVX?
TOVX trades at a trailing price-to-earnings (P/E) ratio of -0.11. Its price-to-book (P/B) ratio is 0.53.
Is TOVX a good stock to buy?
This page provides a data-driven analysis of TOVX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.